The stock of Adicet Bio Inc. (NASDAQ:ACET) decreased by -$0.08 on Friday to finish at $1.67, down -4.57 percent. The last five days have seen an average of 687,400 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$7.2700. The average number of shares traded over the last 20 days was 548,500, while the average volume over the last 50 days totaled 1,070,940.
ACET stock dropped -33.20% since last month. On 08/25/23, the company’s shares reached a one-month low of $1.6600. The stock touched a high of $21.87 on 02/02/23, after rallying from a low of $1.73 in 52 weeks. The price of ACET stock has declined by -81.32% or -$7.2700 this year, reaching a new high 3 times. Still, the stock price is down -92.36% from the 52-week high.
Insider Transactions
ACET stock investors should be aware that Adicet Bio Inc. (ACET) stock had its last reported insider trading activity 59 days ago on Jun 30. On Jun 30, Director DUBIN STEVE acquired 5,000 shares at $2.40 each. This transaction resulted in the insider spending $12,000. On Jun 27, GORDON CARL L added 875,000 shares at a price of US$2.09. After the transaction, the insider now owns 5,685,259 shares. Director ORBIMED ADVISORS LLC had earlier bought 875,000 shares on Jun 27 for $2.09 a share. The transaction was completed for $1,828,750.
Valuation Metrics
Company paid $0.01 per share in dividends, remained unchanged from $0.01 last year.
Financial Health
For the three months ended June 29, Adicet Bio Inc.’s quick ratio was 11.10, while its current ratio was 11.10, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $97.54 million and revenue of $24.99 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ACET’s return on assets (ROA) during the last 12 months has been -36.30%. There was a -24.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -41.30%.
Earnings Surprise
According to Adicet Bio Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that Adicet Bio Inc.’s quarterly earnings would be -$0.75, but it ended up being -$0.68, beating the consensus by -10.30%. EBITDA was -$33.37 million for the quarter. At the end of Adicet Bio Inc.’s most recent quarter ended June 29, its liabilities totaled 38.57 million, while its total debt was $22.64 million. Equity owned by shareholders amounts to $43.07 million.
Technical Picture
Here’s a quick look at Adicet Bio Inc.’s (ACET) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 20.34%, suggesting the stock is oversold, with a 31.96% historical volatility rate.
The stochastic %K and %D were 2.03% and 2.25% respectively, while the average true range (ATR) was 0.1578. Based on the 14-day stochastic reading of 1.28%, the RSI (14) reading is 26.13%. On the 9-day MACD Oscillator, the stock is at -0.1533, and the 14-day reading is at -0.2764.
Analyst Ratings
Adicet Bio Inc. (NASDAQ: ACET) was downgraded by JMP Securities to a a Mkt perform rating in its latest research report. The stock was previously rated as a a Mkt outperform. Analysts have assigned Adicet Bio Inc. (ACET) an Overweight rating. ACET is a stock that is recommended for selling by 0 brokerage firms, while 4 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is ACET’s price target for the next 12 months?
The current consensus forecast for the stock is between $10.00 and $28.00, with a median target price of $25.00. In analyzing these forecasts, the average price target given by analysts for Adicet Bio Inc. (ACET) is $21.00.
